Search Results

- Agreement to characterize gene expression and immunological signature of tumors - SkylineDx focuses on discovery and development of novel gene-based biomarkers

SkylineDx announced, during the European Society for Medical Oncology congress, that it successfully validated the performance of their skin cancer diagnostic test on the first, independent, European dataset.

SkylineDx announced at the 32nd Biennial Dermatology Symposium: The O’Leary Meeting 2019 in Rochester the launch of a pilot study it will conduct with the Mayo Clinic to evaluate and optimize its diagnostic services focused on primary cutaneous melanoma.

Quest Diagnostics announced the launch of MelaNodal Predict™, a highly advanced predictive gene expression test to help personalize treatment decisions for patients with melanoma, the deadliest form of skin cancer and one of the most common cancers in the United States.1 Dermatologists and other providers nationwide may begin ordering the test today from Quest Diagnostics, as well as through Dermpath Diagnostics, Quest’s subspecialty pathology business.

For SkylineDx, the collaboration with the renowned Mayo Clinic is an important milestone as it allows the company to develop new diagnostic tests and extend its product offering for a broader group of patients and clinicians.

The Rotterdam headquartered diagnostics company has been granted CAP accreditation, following its CLIA certification in December 2018 and became the first Dutch scale-up with a CAP and CLIA certified clinical laboratory in San Diego, joining an elite group of globally recognized facilities that operate at the highest level of quality laboratory standards.

SkylineDx signed a collaboration agreement with a multi-disciplinary clinical consortium in the Netherlands that designed a trial to implement a diagnostic innovation to manage continuity of care delivery when resources are under pressure due to COVID.

Benelux’ largest biotech investor Aat van Herk commits a €20 million investment in diagnostics company SkylineDx after reaching major milestones in 2018, financing SkylineDx’ market potential of over $1 billion annually based on their current progress in the melanoma field.

SkylineDx is excited to announce the scientific collaboration with the Multiple Myeloma (blood cancer) specialized department of the Wuerzburg University Medical Center II under the leadership of Prof. Dr. med. Martin Kortüm and Dr. med. Leo Rasche.